These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9561203)

  • 1. Sensitivity to inhibition and catalytic efficiency of HIV proteinase mutants.
    Wilson SI; Phylip LH; Gulnik SV; Mills JS; Bur D; Dunn BM; Kay J
    Adv Exp Med Biol; 1998; 436():85-9. PubMed ID: 9561203
    [No Abstract]   [Full Text] [Related]  

  • 2. Computer assisted evaluation of inhibitor sensitivity to HIV-1 PR mutants.
    Sussman F; Martínez LA; Villaverde MC
    Adv Exp Med Biol; 1998; 436():91-7. PubMed ID: 9561204
    [No Abstract]   [Full Text] [Related]  

  • 3. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.
    Lam E; Parkin NT
    Clin Infect Dis; 2003 Nov; 37(9):1273-4. PubMed ID: 14557976
    [No Abstract]   [Full Text] [Related]  

  • 4. Predicting drug-resistant mutations of HIV protease.
    Ishikita H; Warshel A
    Angew Chem Int Ed Engl; 2008; 47(4):697-700. PubMed ID: 18058968
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV protease mutations leading to reduced inhibitor susceptibility.
    Korant B; Lu Z; Strack P; Rizzo C
    Adv Exp Med Biol; 1996; 389():241-5. PubMed ID: 8861017
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterization of HIV-1 protease mutants: random, directed, selected.
    Swanstrom R
    Curr Opin Biotechnol; 1994 Aug; 5(4):409-13. PubMed ID: 7765174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
    Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
    J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
    Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
    J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
    Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
    Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining mutations in HIV-1 protease to understand mechanisms of resistance.
    Mahalingam B; Boross P; Wang YF; Louis JM; Fischer CC; Tozser J; Harrison RW; Weber IT
    Proteins; 2002 Jul; 48(1):107-16. PubMed ID: 12012342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. I36T↑T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions.
    Maseko SB; Padayachee E; Govender T; Sayed Y; Kruger G; Maguire GEM; Lin J
    Biol Chem; 2017 Sep; 398(10):1109-1117. PubMed ID: 28525359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of a macromolecular inhibitor of HIV-1 protease.
    Dauber DS; McPhee F; Unal A; Craik CS
    Adv Exp Med Biol; 1998; 436():65-70. PubMed ID: 9561201
    [No Abstract]   [Full Text] [Related]  

  • 14. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.
    Velazquez-Campoy A; Todd MJ; Vega S; Freire E
    Proc Natl Acad Sci U S A; 2001 May; 98(11):6062-7. PubMed ID: 11353856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
    Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
    Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A unidirectional crosslinking strategy for HIV-1 protease dimerization inhibitors.
    Hwang YS; Chmielewski J
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4297-300. PubMed ID: 15261290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific interaction between HIV-1 proteinase and 5'-phosphate peptidomimetic derivatives of nucleoside analogues.
    Nillroth U; Besidsky Y; Classon B; Chattopadhyaya J; Ugi I; Danielson UH
    Drug Des Discov; 1995 Aug; 13(1):43-54. PubMed ID: 8882900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus. Protease uninhibited.
    Richman DD
    Nature; 1995 Apr; 374(6522):494. PubMed ID: 7700370
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
    de Mendoza C; Garrido C; Corral A; Zahonero N; Soriano V
    AIDS; 2008 Jan; 22(2):311-3. PubMed ID: 18097236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.